Taking peoplePhase 1
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Key facts
- Who runs it
- Chugai Pharmaceutical Co. Ltd.
- Where
- Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, and Spain37 sites in 14 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 78 people, planned
- Started
- 28 Mar 2025
- Expected to end
- 28 Dec 2026
- Type of study
- Interventional
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
This trial has no sites in United States.
It has sites in 14 countries. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Record updated
- 2 November 2026